ABSTRACT
Differential diagnosis of tuberculosis (TB) and latent TB infection (LTBI) remains a public health priority in high TB burden countries. Pulmonary TB is diagnosed by sputum smear microscopy, chest X-rays, and PCR tests for distinct Mycobacterium tuberculosis (Mtb) genes. Clinical tests to diagnose LTBI rely on immune cell stimulation in blood plasma with TB-specific antigens followed by measurements of interferon-γ concentrations. The latter is an important cytokine for cellular immune responses against Mtb in infected lung tissue. Sputum smear microscopy and chest X-rays are not sufficiently sensitive while both PCR and interferon-γ release assays are expensive. Alternative biomarkers useful for developing diagnostic tests to discern TB disease states are desirable. This study’s objective was to discover biomarkers in sputum, assessing the proteomes and microbiomes of 74 TB patients, 46 individuals with LTBI, and 51 negative community controls (NCC). Study participants were from the South Omo province, a pastoral region in southern Ethiopia. A total of 161 and 115 samples were used to determine the 16S rRNA sequence-based bacterial taxonomies and proteomic profiles, respectively. Sputum microbiota did not reveal statistically significant differences in α-diversity comparing the three groups. The genus Mycobacterium, representing Mtb, was only identified for the TB group. The latter featured reduced abundance of the genus Rothia in comparison to the LTBI and NCC groups. Rothia is a human respiratory tract commensal and may be sensitive to the inflammatory milieu caused by TB infection. Proteomic data strongly supported innate immune responses against Mtb in subjects with pulmonary TB. Ferritin, an iron storage protein released by damaged host cells, was markedly increased in abundance in TB sputum compared to the LTBI and NCC groups, along with α-1-acid glycoproteins ORM1 and ORM2. These proteins are acute phase reactants and inhibit excessive neutrophil activation. Proteomic data also supported effector roles of neutrophils in the anti-Mtb response which was not observed for LTBI cases. Less abundant in sputum of the LTBI group versus the NCC group were two immunomodulatory proteins, mitochondrial TSPO and the extracellular ribonuclease T2. If validated, these proteins are of interest as diagnostic biomarkers for LTBI.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This study served to identify clinical biomarker candidates for latent and active tuberculosis, enrolling Ethiopian patients and community controls. The study was approved by review boards (IRBs, ethics committees) of the participating institutions, assessing ethics, informed consent and human subject protection.
Funding Statement
This work was supported by funds from the grant 1U01HG007472 (National Institutes of Health, USA). The grantor had no role in this publication effort. No payments or services were received by any author from a 3rd party.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human subject recruitment occurred in a multi-ethnic southern Ethiopian region (South Omo province). Covering eight districts, a study named Systems Biology for Molecular Analysis of Tuberculosis in Ethiopia resulted in informed consent of ∽ 2,100 individuals aged 15 years or older at local or regional clinics. Some individuals had symptoms consistent with TB. Negative community controls (NCC) often were household contacts of those suspected to be infected with TB. Nearly 1,200 sputum and blood samples were collected. Of those, nearly 13% were positive using acid-fast bacilli (AFB) smear microscopy or by isolating Mycobacterium tuberculosis complex (MTBC) strains on Lowenstein Jensen medium [31]. Subjects positive for PTB were offered DOTS treatment at a clinic close to their residences. Information on geographic and socio-economic characteristics, ethnic affiliations, exclusion from participation, and other medical data were reported recently. The Institutional Review Board at Aklilu Lemma Institute of Pathobiology, Addis Ababa University (ALIPB-AAU) under ref. no. ALIPB/IRB/22-B/2012/13, the National Research Ethics Committee of Ethiopia (ref no. 3.10/785/07), and the J. Craig Venter Institute (JCVI) IRB (ref. no. 2014-200) approved the human subject protocol.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The study was observational and served to understand different disease outcomes of tuberculosis via biomarker identifications. Cohort recruitment data on record are provided in Supplemental Files. Human subject enrollment and approvals were described in two previously peer-reviewed and published articles using the same cohort. 1. BMC Public Health. 2018 Feb 17;18(1):266. doi: 10.1186/s12889-018-5149-7. 2. Infect Immun. 2018 Mar 22;86(4):e00759-17. doi: 10.1128/IAI.00759-17
